New Technologies for Influenza Vaccines
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vac...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/8/11/1745 |
id |
doaj-1716ea41f83e48b9baeaab7e4e19bf41 |
---|---|
record_format |
Article |
spelling |
doaj-1716ea41f83e48b9baeaab7e4e19bf412020-11-25T04:02:15ZengMDPI AGMicroorganisms2076-26072020-11-0181745174510.3390/microorganisms8111745New Technologies for Influenza VaccinesSteven Rockman0Karen L. Laurie1Simone Parkes2Adam Wheatley3Ian G. Barr4Technical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaTechnical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaTechnical Development, Seqirus Ltd, Parkville, VIC 3052, AustraliaDepartment of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3052, AustraliaDepartment of Immunology and Microbiology, The University of Melbourne, Parkville, VIC 3052, AustraliaVaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.https://www.mdpi.com/2076-2607/8/11/1745influenzavaccineuniversal vaccinecell-cultureegg-based influenza vaccinescell-based influenza vaccines |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Steven Rockman Karen L. Laurie Simone Parkes Adam Wheatley Ian G. Barr |
spellingShingle |
Steven Rockman Karen L. Laurie Simone Parkes Adam Wheatley Ian G. Barr New Technologies for Influenza Vaccines Microorganisms influenza vaccine universal vaccine cell-culture egg-based influenza vaccines cell-based influenza vaccines |
author_facet |
Steven Rockman Karen L. Laurie Simone Parkes Adam Wheatley Ian G. Barr |
author_sort |
Steven Rockman |
title |
New Technologies for Influenza Vaccines |
title_short |
New Technologies for Influenza Vaccines |
title_full |
New Technologies for Influenza Vaccines |
title_fullStr |
New Technologies for Influenza Vaccines |
title_full_unstemmed |
New Technologies for Influenza Vaccines |
title_sort |
new technologies for influenza vaccines |
publisher |
MDPI AG |
series |
Microorganisms |
issn |
2076-2607 |
publishDate |
2020-11-01 |
description |
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine. |
topic |
influenza vaccine universal vaccine cell-culture egg-based influenza vaccines cell-based influenza vaccines |
url |
https://www.mdpi.com/2076-2607/8/11/1745 |
work_keys_str_mv |
AT stevenrockman newtechnologiesforinfluenzavaccines AT karenllaurie newtechnologiesforinfluenzavaccines AT simoneparkes newtechnologiesforinfluenzavaccines AT adamwheatley newtechnologiesforinfluenzavaccines AT iangbarr newtechnologiesforinfluenzavaccines |
_version_ |
1724443715127214080 |